SELLAS Life Sciences Group WKN: A2PU3T ISIN: US81642T2096 Forum: Aktien Thema: Hauptdiskussion

Bin ich auf morgen Abend gespannt. Dann wäre die Inovio Lücke geschlossen 😊

Harvey 🤣🤗 🙋‍♀️

Sowas muss man mitnehmen

Läuft ja jetzt

Bin auch dabei ✌😂

Danke 👌🏻

Bei uns da so gegen 19 uhr

Also zwischen 14.15 und 15.30 amerikanischer zeit

SELLAS Life Sciences Group Inc. (SLS) is up more than 70% at $10.99 in pre-market hours, adding to yesterday's gain of over 70%, on no news. The company is slated to present finalized data from the National Cancer Institute-sponsored phase II trial of Nelipepimut-S in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in women with ductal carcinoma in situ (DCIS) of the breast who are HLA-A2 or A3 positive, express HER2 at IHC 1 , 2 , or 3 levels, and are pre- or post-menopausal, at the 2020 San Antonio Breast Cancer Symposium on December 11.

komischer Weise macht Sellas und Immutep gleichzeitig Deals in China

Ich auch.. jetzt zieht es gerade wieder ein bisserl an

kein Ding. Da bin ich morgen gespannt

Danke markoll

SELLAS is slated to present finalized data from the National Cancer Institute-sponsored phase II trial of Nelipepimut-S in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in women with ductal carcinoma in situ (DCIS) of the breast, at the 2020 San Antonio Breast Cancer Symposium on Friday, December 11.

RTTNews) - Shares of biopharmaceutical company SELLAS Life Sciences Group, Inc. (SLS) are extending strong gains from the previous sessions and rising more than 14 percent or $0.90 in Thursday's morning trade at $7.29, after hitting a new 52-week high of $9.29. Earlier this week, SELLAS Life Sciences and China-based biopharmaceutical company 3D Medicines Inc. said they have entered into an exclusive license agreement. The license deal grants rights to 3DMed to develop and commercialize SELLAS' lead late-stage clinical candidate, galinpepimut-S or GPS, as well as its next generation heptavalent immunotherapeuatic, GPS , which is at preclinical stage, across all therapeutic and diagnostic uses in the Greater China territory. SELLAS retains sole rights to GPS and GPS outside of the Greater China area. Potential payments to SELLAS under the agreement could total $202 million in license fees and milestone payments, not including future royalties.

Soom 👌😉🤣